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SINGLE INSTILLATION OF MITOMYCIN C REDUCES 1ST YEAR 
RECURRENCE FOLLOWING TRANSURETHRAL RESECTION OF 
NON-MUSCLE INVASIVE BLADDER CANCER 
M. Hammad Ather, S Aziz, M N Sulaiman  
Department of Surgery, The Aga Khan University Hospital, Karachi, Pakistan  
Objective: To study the impact of single instillation of 40 mg Mitomycin C (MMC-40) within first 
hour of transurethral resection (TUR), on first year recurrence of non-muscle invasive bladder 
cancer. Methods: In this study of two groups of patients with similar demographics and tumour 
profile were compared to assess first year tumour recurrence pattern. Group A received MMC-40 
within 30 minutes of TUR. Group B patients only had TUR of bladder tumour. Patients’ charts were 
reviewed for demographic profile, preoperative diagnosis and imaging used, cytological work up, 
tumour profile both during cystoscopy and imaging used, patients records were also reviewed for all 
subsequent check cystoscopies for recurrence. Any adjuvant treatments like intravesical 
chemo/immunotherapy etc. were also noted. The results were analysed using a commercially 
available statistical package, SPSS™. The level of significance was 0.05. Results: There were 29 
and 46 patients in group A and B respectively. The demographic profile in terms of age, gender 
distribution, tumour characteristics (size, site, multiplicity) and pathological evaluation including, 
tumour grade and presence of carcinoma in situ were similar (p<0.4 and p<0.5) respectively. The 
first year recurrence rate in group A was 15% whereas it was 37.4% in group B (p<0.04). 
Conclusions: The first year recurrence rate is significantly decreased if MMC-40 is instilled 
following TUR. MMC-40 is safe and cost effective. Most low grade, low volume tumours would not 
require any further treatment if MMC-40 is given immediately following TUR. 
Key words: non-muscle invasive bladder cancer, single instillation of chemotherapeutic agent, 
recurrence 
INTRODUCTION 
Bladder cancer is the second commonest urological 
malignancy in the world1 and commonest in Pakistan. 
In United States in year 2006, estimated 61420 new 
cases are diagnosed.1 Majority of bladder cancers 
presents as superficial transitional cell cancers. 
Superficial tumours have a high rate of recurrence (25-
40%) in the first year2 following transurethral resection 
(TUR). Following TUR intravesical treatment of either 
immunotherapeutic agent, Bacillus Calmette-Guérin 
(BCG), or a chemotherapeutic agent like Mitomycin C 
(MMC) is considered to avoid recurrence. However, in 
majority of cases it is an over treatment in patients 
with low risk cancers. Transurethral resection of the 
tumour is considered as treatment of choice in non-
muscle invasive bladder cancer. A number of studies 
agree with the fact that intravesical instillation of 
cytotoxic agents within the first hours after operation 
reduces the risk of tumour recurrence.3 It is assumed 
that transurethral resections of bladder tumours evoke 
relevant intravesical tumour cell suspensions. Thus, 
reimplantation of tumour cells and consequently a 
cancer recurrence are promoted.4 In this case, early 
intravesical instillations of chemotherapeutic agents 
such as Mitomycin or Epirubicin have cytotoxic and 
preventive effects. Side effects of intravesical 
instillation are uncommon, and therefore, this therapy 
is considered to be simple and safe.5 In the current 
work we have looked at the efficacy, of administration 
of 40 mg of MMC in the recovery room in prevention 
of 1st year recurrence of non-muscle invasive bladder 
cancer. 
MATERIAL AND METHODS 
This is a comparative study conducted to assess the 
impact of 40 mg of Mitomycin C (MMC-40) on 
recurrence in the first year following TUR. Patients 
were divided in two groups with similar demographic 
and tumour profile. The difference between first year 
recurrence pattern, toxicity and safety of SICA was 
compared in the two groups. Group A received MMC-
40 within 60 minutes of transurethral resection, in the 
recovery room, if the surgeon believes there is no overt 
perforation and bladder injury during TUR. Group B 
patients only had TUR of bladder tumour. 
The patients were identified from the medical 
records coding and indexing6 (ICD 9 Cm) using 
bladder cancer, TUR and MMC as key words. 
Patients’ charts were reviewed for demographic 
profile, preoperative diagnosis and imaging used, 
cytological work up, tumour profile both during 
cystoscopy and pre-operative imaging used, patients 
records were also reviewed for all subsequent check 
cystoscopies for recurrence. Any complications related 
to the SICA were also noted. To assess the cost 
effectiveness of SICA, the additional cost of SICA 
need for over stay in recovery room was analysed and 
compared with the maintenance dose of 6 cycles in out 
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patient set up. The resected tumour, along with cold 
cup biopsies from the tumour base and random 
biopsies, if taken were sent for histopathology. The 
tumour staging was done using the 1997 TNM 
classification of bladder cancer. The tumour grading 
was done according to the WHO/ISUP system. 
Any adjuvant treatments like intravesical 
chemo/immunotherapy etc. were also noted. Results 
were analysed using a commercially available 
statistical package, SPSS™. 
RESULTS 
There were 29 patients in group A and 46 in group B 
(Table-1). The mean age of patient in the group A 
was 55.513.7 and 53.515.8 years. There were 90% 
males in group A and 89% in group B. The clinical 
presentation in the two groups was similar. 
 Table-1. Demographic profile and presentation 




Age (Years) MeanSD 55.513.7 53.515.8 
Gender (M:F) 27:2 41:5 
Gross haematuria (%) 78 89 
Microscopic haematuria (%) 7 3 
LUTS % 42 37 
p<0.4 
The cystoscopic findings (Table-2) in the two 
groups showed that in group A, two third of patients 
had multiple tumours whereas in group B 81% had 
multiple tumours. Eighty-nine percent and 86% 
tumours had papillary configuration in group A and B 
respectively. Seven percent were sessile in both groups 
and 4% in group A and 7% in group B had both sessile 
and papillary tumours. The mean size in group A was 
3.31.7 Cm and in group B it was 3.42.1 Cm. 
random biopsies were taken in 22% cases in group A 
and in 40% in group B. 
Table-2: Cystoscopic findings 
 Group A (n=29) Group B (n=46) 
Multiple  33% 16% 
Papillary  89% 86% 
Pathological evaluation (Figure-1) indicated 
that 96.5% and 91% respectively were T1 cancers in 
group A and B respectively. The recurrence at 1st year 
follow up showed a significant difference (p<0.04) in 
the two groups (Figure-2). 
The cost of single instillation of 40 mg. 
MMC in the recovery room is PKR 3,000 (~50 US $) 
compared to 6 cycles of MMC 20 mg in the clinic 
PKR ~12,000 (~200 US $) (p<0.001). 
DISCUSSION 
Worldwide an estimated 356,600 new cases of bladder 
cancer occur each year and, in terms of overall cancer 
frequency, it is ranked as ninth.7 The highest incidence 
rates are generally found in industrially developed 
countries, particularly in North America and Western 
Europe, and in areas associated with endemic 
schistosomiasis in Africa and Middle East. Bladder 
cancer is more common in men than women, with a 
worldwide male/female ratio of 10:3.3 
Patients with superficial bladder carcinoma 
can be expected to have recurrences after TUR. 
Recurrence rates were reported as 30–90% according to 
prognostic factors. Chemotherapeutic agents or BCG 
often were administered into the bladder to prevent or 
delay the recurrences.8 To date, the instillation strategy 
should be chosen according to risk criteria.8-10 TUR 
alone is still the standard treatment for low-risk patients, 
e.g., patients with a single bladder carcinoma.11,12 
However, the immediate instillation of a 
chemotherapeutic agent after TUR has become an 
alternative option since Oostelinck et al and Tolley et al 
reported on its validity.13,14 
Figure-1: Pathological evaluation of tumour 
  
Figure-2: Recurrence at 1st year of follow up 
(p<0.04) 
 
The therapeutic objectives in initial treatment 
of superficial tumours are to remove completely the 
tumour, to assess the need for further therapy and to 
plan the follow-up.  The EORTC Genitourinary Group 
assessed the percentage of patients with recurrence at 3 
months after complete resection of all visible lesions 
taking into account the institution, number of tumours 
at presentation and the year of treatment.2 For single 
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and for multiple tumours from 7 to 75%. The 3-month 
recurrence by number of tumours was 8.7% for single 
tumours, 21% for 2–5 tumours and 32.2% for >5 
tumours. The 3-month recurrence by year of entry for 
single tumours ranged from 21.0 to 43.8% during 
1975–1978, from 6.3 to 12.7% during 1984-1986 and 
from 3 to 5.3% during 1987–1989. For multiple 
tumours it ranged from 50.0 to 61.5% during 1975–
1978, from 20.2 to 27.3% during 1979–1983 and from 
14.4 to 24.6% during 1984–1986. The use of more 
refined instruments probably led to decreasing 
percentage of the 3-month recurrence in more recent 
years, the large variation between institutions remains 
unexplained. The bladder's unique location renders its 
mucosa accessible to instillation of chemotherapeutic 
and immunotherapeutic agents. Cytostatics can be 
instilled into the bladder hours after surgery without 
severe complications. A single early instillation within 
6 hours after transurethral resection (TUR) in patients 
with a solitary bladder tumour category T(a)/T(1) G(1) 
to G(3) could reduce the recurrence rate per year by 
nearly 50%. The superiority of any of the commonly 
used intravesical drugs has never been demonstrated; 
the time to initiate therapy is important for treatment 
outcome. Optimal results can be achieved by initiating 
treatment early (within 24 hours after TUR) and for a 
duration of 6 months, and maintenance (>6 months) 
for patients with a delayed first instillation (>7 days 
after TUR). Our study also presented the 1st year 
recurrence rate as 37.4% in the controlled group and 
15% in the study group. 
Transurethral resection of a bladder tumour 
alone has been recommended for low risk patients, but 
the substantial recurrence rates affected even the low-
risk patients because they subsequently underwent 
TUR-Bt again. Recently, some studies have revealed 
that a single instillation immediately after TUR-Bt 
prevents recurrences.13-14 Oosterlinck et al first 
demonstrated that a single instillation clearly prevented 
recurrence for patients with a single tumor.13 Tolley et al 
stated that a single instillation can prevent recurrences of 
patients with either a single or multiple tumours.14 In 
this study, we demonstrated the prophylactic effect of 
THP for patients with a single superficial bladder 
carcinoma. The net benefit was 25.4% at 1 year, 27.0% 
at 2 years and 21.5% at 3 years.14  
CONCLUSION 
A single immediate intravesical instillation 
after TUR prevents recurrences for patients with a 
single superficial bladder carcinoma, without serious 
complications. We believe that a single immediate 
instillation of MMC-40 should become the standard, 
which might have the advantage of excellent cost 
effectiveness.  
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